Skip to main content
×
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 1
  • Cited by
    This chapter has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Obed, Aiman Bashir, Abdalla Stern, Steffen and Jarrad, Anwar 2018. Severe acute alcoholic hepatitis and liver transplant: A never-ending mournful story. Clinical and Molecular Hepatology, Vol. 24, Issue. 4, p. 358.

    ×
  • Print publication year: 2008
  • Online publication date: August 2009

6 - Alcoholic Liver Disease

Summary

INTRODUCTION

Alcohol is a socially accepted hepatotoxin and its abuse costs approximately $200 billion annually. In the U.S. population, 7–10% meets the diagnostic criteria for alcohol abuse or alcoholism. Alcohol accounts for 40–50% of all the deaths due to cirrhosis and remains the most common cause of liver-related mortality. However, alcoholic liver disease (ALD) represents a spectrum of histologic changes as shown in Table 6.1 with different clinical outcomes.

The mortality rate of alcoholic fatty liver is insignificant, while the age adjusted death rate for alcoholic cirrhosis is 3.8 per 100,000. The five- and 10-year survival rates for alcoholic cirrhosis without liver transplantation are 23% and 7%, respectively, which is significantly less than other forms of cirrhosis (see Table 6.2).

RISK FACTORS

However, it has been estimated that although 75–100% of heavy drinkers show evidence of fatty liver, only 8–20% of patients will develop cirrhosis. Therefore, other factors must play a role in placing these individuals at risk for developing more severe forms of ALD. A number of risk factors have been proposed as shown in Figure 6.1, but none of them can either singly or in combination completely explain the reason why only a minority of individuals ingesting large amounts of alcohol develop ALD.

Quantity of Alcohol Ingested

The quantity of alcohol ingested is the most important risk factor (Table 6.3). Although most investigators agree that those who drink heavily (4–5 drinks per day) are at risk for ALD, others.

Recommend this book

Email your librarian or administrator to recommend adding this book to your organisation's collection.

Practical Management of Liver Diseases
  • Online ISBN: 9780511547416
  • Book DOI: https://doi.org/10.1017/CBO9780511547416
Please enter your name
Please enter a valid email address
Who would you like to send this to *
×
REFERENCES
Dawson, DA, Grant, BF, Chou, SP, Pickering, RP. Subgroup variation in the U.S. drinking patterns: Results of the 1992 National Longitudinal Alcohol Epidemiologic Study. J Subst Abuse 1995;7:331–4.
Jamal MM, Mandavam S., Morgan, TR. Epidemiology of alcoholic liver disease. Semin Liver Dis 2004;24:217–32.
Jamal, MM, Morgan, TR. Liver disease in alcohol and hepatitis C. Best Pract Res Clin Gastroenterol 2003;17:649–62.
O'Shea, RS, McCullough, AJ. Treatment of alcoholic hepatitis. Clin Liver Dis 2005;9:103–34.
Dam-Larsen, S, Franzmann, M, Andersen, IB, Christoffersen, P, et al. Long-term prognosis of fatty liver: Risk of chronic liver disease and death. Gut 2004;53:750–5.
Singh, GK, Hoyert, DL. Social epidemiology of chronic liver disease and cirrhosis mortality in the United States 1935–1977: Trends and differentials by ethnicity, socioeconomic status and alcohol consumption. Hum Biol 2000;72:801–20.
Bellentani, S, Saccoccio, G, Costa, G, Tiribelli, C, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. Gut 1997;41:845–50.
Kamper-Jorgensen, M, Gronbaek, M, Tolstrup, J, Becker, U. Alcohol and cirrhosis: dose-response or threshold effect?J Hepatol 2004;41:25–30.
Becker, U, Gronbaek, M, Johansen, D, Sorensen, TI. Lower risk for alcohol-induced cirrhosis in wine drinkers. Hepatology 2002;35:868–75.
Barrio, E, Tome, S, Rodriguez, I, Gude, F, et al. Liver disease in heavy drinkers with and without alcohol withdrawal syndrome. Alcohol Clin Exp Res 2004;28:131–36.
Tolstrup, JS, Jensen, MK, Tjonneland, A, Overvad, K, Gronback, M. Drinking pattern and mortality in middle-aged men and women. Addiction 2004;99:323–30.
Lu, XL, Luo, JY, Tao, M, Gen, Y, Zhao, P, et al. Risk factors for alcoholic liver disease in China. World J Gastroenterol 2004;10:2423–6.
French, SW. The role of hypoxia in the pathogenesis of alcoholic liver disease. Hepatol Res 2004;29:69–74.
Mansouri, A, Gaou, I, DeKerguenec, C, Amsellem, S, et al. An alcoholic binge causes massive degradation of hepatic mitochondrial DNA in mice. Gastroenterology 1999;117:181–90.
Loft, S, Olesen, KL, Dossing, M. Increased susceptibility to liver disease in relation to alcohol consumption in women. Scand J Gastroenterol 1987;22:1251–6.
Becker, U, Deis, A, Sorensen, TI, Gronbaek, M, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: A prospective population study. Hepatology 1996;23: 1025–9.
Lelbach, WK. Epidemiology of alcoholic liver disease. Prog Liv Dis 1976;5:494–515.
Crabb, DW. Pathogenesis of alcoholic liver disease: Newer mechanisms of injury. Keio J Med 1999;48:184–8.
Poynard, T, Bedossa, P, Opolon, P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancer 1997;349:825–32.
Bellentani, S, Pozzato, G, Saccoccio, G, Crovatto, M, Croce, LS, et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: Report from the Dionysos study. Gut 1999;44:874–80.
Corrao, G, Arico, S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology 1998;27:914–19.
Hezode, C, Lonjon, I, Roudot-Thoraval, F, Pawlotsky, JM, Safrani, ES, Shumeaux, D. Impact of moderate alcohol consumption on histological activity and fibrosis in patients with chronic hepatitis C, and specific influence of steatosis: a prospective study. Aliment Pharmacol Ther 2003;17:1031–7.
Monto, A, Patel, K, Bostrom, A, Pianko, S, et al. Risks of a range of alcohol intake on hepatitis C-related fibrosis. Hepatology 2004;39:826–34.
Freeman, AJ, Dore, GJ, Law, MG, Thorpe, M, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001 Oct;34(4 Pt1):809–16.
Hutchinson, SJ, Bird, SM, Goldberg, DJ. Influence of alcohol on the progression of hepatitis C virus infection: A meta-analysis. Clin Gastroenterol Hepatol 2005;3(11): 1150–9.
Tsui, JI, Pletcher, MJ, Vittinghoff, E, Seal, K, Gonzales, R. Hepatitis C and hospital outcomes in patients admitted with alcohol-related problems. J Hepatol 2006;44: 262–6.
Yokoyama, H. Ishii H, Moriya, S, Magata, S, Watanabe, T, Kamegaya, K, et al. Relationship between hepatitis C virus subtypes and clinical features of liver disease seen in alcoholics. J Hepatol 1995;22:130–4.
Fasani, P, Sangiovanni, A, DeFazio, C, Borzio, M, Bruno, S, Ronchi, G, et al. High prevalence of multinodular hepatocellular carcinoma in patients with cirrhosis attributable to multiple risk factors. Hepatology 1999;29:1704–7.
Marsano, LS, Pena, LR. The interaction of alcoholic liver disease and hepatitis C. Hepatogastroenterology 1998;45:331–9.
Monto, A, Wright, TL. The epidemiology and prevention of hepatocellular carcinoma. Semin Oncol 2001;28:441–9.
Sarin, SK, Dhingra, N, Bansal, A, Malhotra, S, Guptan, RC. Dietary and nutritional abnormalities in alcoholic liver disease: A comparison with chronic alcoholics without liver disease. Am J Gastroenterol 1997;92:777–83.
Leevy, CM, Moroianu, SA. Nutritional aspects of alcoholic liver disease. Clin Liver Dis 2005;9:67–81.
Iturriaga, H, Bunont, D, Hirsch, S, Ugarte, G. Overweight as a risk factor or a predictive sign of histological liver damage in alcoholics. Am J Clin Nutri 1988;47:235–8.
Naveau, S, Giraud, V, Borotto, E, Aubent, A, Capron, F, Chaput, JC. Excess weight as a risk factor for alcoholic liver disease. Hepatology 1997;25:108–11.
Lu, XL, Luo, JY, Tao, M, Gen, Y, Zhao, P, Zhao, HL. Risk factors for alcoholic liver disease in China. World J Gastroenterol 2004;10:2433–66.
Mezey, E. Dietary fat and alcoholic liver disease. Hepatology 1998;28:901–9.
Mathurin, P, Is alcoholic hepatitis an indicator for transplantation? Current management and outcomes. Liver Transplantation 2005;11(suppl 1): 21–4.
Kurner, T, Kropf, J, Kosche, R, Kristal, H, Jaspersen, D, Gressner, AM. Improvement of prognostic power of the Child-Pugh classification of liver cirrhosis by hyaluronan. J Hepatol 2003;39:947–53.
Orrego, H, Israel, Y, Blake, JE, Medline, A. Assessment of prognostic factors in alcoholic liver disease toward a global quantitative expression of severity. Hepatology 1983;3:896–905.
Maddrey, WC. Alcoholic hepatitis: Clinicopathologic features and therapy. Semin Liv Dis 1988;8:91–102.
Mathurin, P, Duchatelle, V, Ramond, MJ, Degott, C, Bedossa, P, et al. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology 1996;110:1847–53.
Sheth, M, Riggs, M, Patel, T. Utility of the Mayo end-stage liver disease. MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol 2002;2:1–5.
Thabut, D, Navean, S, Charlotte, F, Massard, J, et al. The diagnostic value of biomarkers. Ash test) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease. J Hepatol 2006;44:1175–85.
Mendenhall, CK. Alcoholic hepatitis. In: SchiffL, L,Schiff, ER, editors. Diseases of the liver. 6th edition. Philadelphia: JB Lippincott Co, 1987, pp. 669–685.
Srikureja, W, Kyola, NL, Runyon, R, Hu, KQ. Meld score is a better prognostic model than Child-Turcotte-Pugh score on discriminant function score in patients with alcoholic hepatitis. J Hepatol 2005;42:700–6.
Mathurin, P, Abdelnour, M, Ramond, MJ, Carbonell, N, Fartoux, L, et al. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology 2003;38:1363–9.
Helman, RA, Temko, MH, Nye, SW, Fallon, HU. Natural history and evaluation of prednisolone therapy. Ann Intern Med 1971;74:311–21.
Porter, HP, Simon, FR, Pope, CE, Volwiler, W, Fenster, LF. Corticosteroid therapy in severe alcoholic hepatitis. N Engl J Med 1971;284:1350–5.
Campra, JL, Hamlin, EM Jr, Kirshbaum, RJ, Olivier, M, Redeker, AG, Reynolds, TB. Prednisone therapy of acute alcoholic hepatitis. Ann Intern Med 1973;79:625–31.
Blitzer, BL, Mutchnick, MG, Joshi, PH, Phillips, MM, Fessel, JM, Conn, HO. Adrenocorticosteroid therapy in alcoholic hepatitis: A prospective, double-blind randomized study. Am J Dig Dis 1977;22:477–84.
Lesesne, HR, Bozymski, EM, Fallon, JH. Treatment of alcoholic hepatitis with encephalopathy. Comparison of prednisolone with caloric supplements. Gastroenterology 1978;74:169–73.
Maddrey, WC, Boitnott, JK, Bedine, MS, Weber, FL Jr, Mezey, E, White, RI Jr. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978;75:193–9.
Shumaker, JB, Resnick, RH, Galambos, JT, Makopour, H, Iber, FL. A controlled trial of 6-methylprednisolone in acute alcoholic hepatitis. Am J Gastroenterol 1978;69:443–9.
Depew, W, Boyer, T, Omata, M, Redeker, A, Reynolds, T. Double-blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy. Gastroenterology 1980;78:524–9.
Theodossi, A, Eddleston, ALWF, Williams, R. Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis. Gut 1982;23:75–9.
Mendenhall, CL, Anderson, S, Garcia-Pont, P, Goldberg, S, et all. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. N Engl J Med 1984;311:1464–70.
Bories, P, Guedj, JY, Mirouze, D, Yousfi, A, Michel, H. Traitement de L'hépatite alcoolique aiguë par la prednisolone. Presse Med 1987;16:769–72.
Carithers, RL Jr, Herlong, HF, Diehl, AM, Shaw, EW, Combes, B, Fallon, HJ, Maddrey, WC. Methylprednisolone therapy in patients with severe alcoholic hepatitis: A randomized multicenter trialAnn Intern Med 1989;11:685–90.
Ramond, MJ, Poynard, T, Rueff, B, Mathurin, P, et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992;326:507–12.
Daures, JP, Peray, P, Bories, P, Blanc, P, Yousfi, A, Michel, H, Gremy, F. Place de la corticotherapyie dans le traitement des hépatite alcoolique aiguë. Resultats dune métaanalyse. Gastroenterol Clin Biol 1991;15:223–28.
Reynolds, TB, Benhamou, JP, Blake, J. Treatment of alcoholic hepatitis. Gastroenterol Int 1989;2:208–16.
Imperiale, TF, McCullough, AJ. Do corticosteroids reduce mortality from alcoholic hepatitis. Ann Intern Med 1990;113:299–307.
Mathurin, P, Mendenhall, CL, Carithers, RL Jr, Ramond, MJ, et al. Corticosteroids improve short term survival in patients with severe alcoholic hepatitis.AH): Individual data analysis of the last three randomized placebo controlled double-blind trials of corticosteroids in severe AH. J Hepat 2002;36:547–8.
Mathurin, P, Duchatelle, V, Ramond, MJ, Degott, C, et al. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology 1996;110:1847–55.
Schicting, D, Juhl, E, Poulsen, H, Winkel, P, and ,the Copenhagen Study Group for Liver Diseases. Alcoholic hepatitis superimposed on cirrhosis, clinical significance of long term prednisolone treatment. Scan J Gastroenterol 1976;22:305–12.
O'Keefe, C, McCormick, PA. Severe acute alcoholic hepatitis: an audit of medical treatment. Med J 2002;95:108–111.
McCullough, AJ, O'Connor, JFB. Alcoholic liver disease: Proposed recommendations for the American College of Gastroenterology. Am J Gastroenterol 1998;93:2022–36.
Jimenez, JL, Punzon, C, Navarro, J, Munoz-Fernandez, MA, Fresno, M. Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor KB and nuclear factor of activated T cells activation. J Pharmacol Exp Ther 2001;299:753–59.
Sanchez, S, Albornoz, L, Bandi, JC, Gerona, S, Mastai, R. Pentoxifylline, a drug with rheological effects, decreases portal pressure in an experimental model of cirrhosis. Eur J Gastroenterol Hepatol 1997;9:27–31.
Akriviadis, E, Botla, R, Briggs, W, Han, S, Reynolds, T, Shakil, O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:1787–91.
Spahr, L, Rubbia-Brandt, L, Frossard, JL, Giostra, E, et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol 2002;37:448–55.
Tilg, H, Jalan, R, Kaser, A, Davies, NA, Offner, FA, Hodges, SJ, Ludwiczek, O, et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 2003;38:518–20.
Naveau, S, Chollet-Martin, S, Dharancy, S, Mathurin, P, Jouet, P, Piquet, MA, et al. ,Foie-Alcool group of the Association Française pour l'Etude du Foie. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004;39:1488–90.
Poynard, T, Thabut, D, Chryssostalis, A, Taieb, J, Ratziu, V. Anti-tumor necrosis factor-alpha therapy in severe alcoholic hepatitis: are large randomized trials still possible?J Hepatol 2004;38:419–25.
Mookerjee, RP, Tilg, H, Williams, R, Jalan, R. Infliximab and alcoholic hepatitis. Hepatology 2004;40:499–500.
McClain, CJ, Hill, DB, Barve, SS. Infliximab and prednisolone: Too much of a good thing?Hepatology 2004;39:1488–90.
Menon, KV, Stadheim, L, Kamath, PS, Wiesner, RH, et al. A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol 2004;99:255–60.
Akerman, PA, Cote, PM, Yang, SG, McClain, C, et al. Long-term ethanol consumption alters the hepatic response to the regenerative effects of tumor necrosis factor alpha. Hepatology 1993;17:1066–73.
Mezey, E, Potter, JJ. A randomized placebo controlled trial of vitamin E for alcoholic hepatitis. J Hepatol 2004:40:40–6.
Maza, MP, Peterman, M, Bunout, D, Hirsh, S. Effects of long-term vitamin supplementation in alcoholic cirrhotics. J Am Coll Nutri 1995;14:192–6.
Wenzel, G, Kuklinski, B, Ruhlmann, C, Ehrhardt, D. Alcohol-induced toxic hepatitis—a “ free radical ” associates disease. Lowering facility by adjuvant antioxidant therapy. Z Gesamte In Med 1993;48:490–6.
Mato, JM, Camara, J, Fernandez, Pas J, Caballeria, L, Coll, S, Caballero, A, et al. S-adenosylmethionine in alcoholic liver cirrhosis: A randomized, placebo-controlled, double-blind, multicenter clinical trial. Hepatol 1999;30:1081–9.
Rambaldi, A, Gluud, C. S-Adenosyl-L-methionine for alcoholic liver diseases. Cochrane Database Syst Rev 2004:3
Purohit, V, Russo, D. S-adenosyl-L-methionine in the treatment of alcoholic liver disease: introduction and summary of the symposium. Alcohol 2002;27:151–4.
Austin, AS, Mahida, YR, Clark, D, Ryder, SD, Freeman, JG. A pilot study to investigate the use of oxypentifylline (pentoxifylline) and thalidomide in portal hypertension secondary to alcoholic cirrhosis. Aliment Pharmacol Ther 2004;19:78–82.
Yokota, T, Oritani, K, Takahashi, I, Ishikawa, J, Maatsuyama, A, Ouchi, N, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000;96:1723–32.
Li, Z, Yang, S, Lin, H, Huang, J, Watkins, PA, et al. Probiotics and antibiotics to TNF inhibit inflammatory activity and improve non-alcoholic fatty liver disease. Hepatology 2003;37:347–50.
Natori, S, Rust, C, Stadheim, LM, Srinivasan, A, Burgart, LJ, Gores, CJ. Hepatocyte apoptosis is a pathologic feature of human alcoholic hepatitis. J Hepatol 2001;34:330–3.
Day, CP. Apoptosis in alcoholic hepatitis: A novel therapeutic target?J Hepatol 2001;34:248–53.
Mutimer, DJ, Burra, P, Neuberger, JM, Hubscher, S, Byuckels, JA, et al. Managing severe alcoholic hepatitis complicated by renal failureQ J Med 1993;86:649–56.
Jalan, R, Sen, S, Steiner, C, Kapoor, D, Alisa, A, Williams, R. Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. J Hepatol 2003;38:104–6.
Mendenhall, CL, Anderson, S, Weesner, RE, Goldberg, SJ, Crolic, KA. ,Protein-calorie malnutrition associated with alcoholic hepatitis. Veterans Administration Cooperative Study Group on Alcoholic Hepatitis. Am J Med 1984;76:211–22.
Nompleggi, DJ, Bonkovsky, HL. Nutritional supplementation in chronic liver disease: an analytical review. Hepatology 1994;19:518–33.
Lochs, H, Plauth, M. Liver cirrhosis: rationale and modalities for nutritional support—the European Society of Parenteral and Enteral Nutrition consensus and beyond. Curr Opin Clin Nutri Metab Care 1999;2:345–9.
McCullough, AJ, Bugianesi, E. Protein-calorie malnutrition and the etiology of cirrhosis. Am J Gastroenterol 1997;92:734–8.
Rambaldi, A, Gluud, C, Rambaldi, A. Propylthiouracil for alcoholic liver disease. Cochrane Database Syst Rev 2005;(4):CD002800.
Rambaldi, A, Gluud, . S-adenosyl-L-methionine for alcoholic liver diseases. Cochrane Review Cochrane Database Syst Rev 2001;4:CD002235.
Rambaldi, A, Gluud, C. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. Cochrane Database Syst Rev 2005;(2):CD002148.
Rambaldi, A, Iaguinto, G, Gluud, C. Anabolic-androgenic steroids for alcoholic liver disease. CochraneDatabase Syst Rev 2003;(1):CD003045.
Safdar, K, Schiff, ER. Alcohol and hepatitis C. Semin Liver Dis 2004;24:305–15.
Mackie, J, Groves, K, Hoyle, A, et al. Orthotopic liver transplantation for alcoholic liver disease: a retrospective analysis of survival, recidivism, risk factors predisposing to recidivism. Liver Transplant 2001;7:418–27.
Burro, P, Lucy, MR. Liver transplantation in alcoholic patients. Transpl Int 2005;18:491–8.
Bellamy, CO, DiMartini, AM, Ruppert, K, et al. Liver transplantation for alcoholic cirrhosis: long term follow-up and impact of disease recurrence. Transplantation 2001;72:619–26.
Gish, RG, Lee, A, Brooks, L, et al. Long-term follow-up of patients diagnosed with alcohol dependence or alcohol abuse who were evaluated for liver transplantation. Liver Transpl 2001;7:581–7.
Stefanini, GF, Biselli, M, Grazi, GL, et al. Orthotopic liver transplantation for alcoholic liver disease: rates of survival, complications and relapse. Hepatogastroenterology 1997;44:1356–9.
Zibari, GGB, Edwin, D, Wall, L, et al. Liver transplantation for alcoholic liver disease. Clin Transplant 1996;10(6 Pt 2):676–9.
Howard, L, Fahy, T. Liver transplantation for alcoholic liver disease. Br J Psychiatry 1997;171:497–500.
Lucey, MR, Brown, KA, Everson, GT, et al. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg 1997;3:628–37.
Osorio, RW, Ascher, NL, Avery, M, et al. Predicting recidivism after orthotopic liver transplantation for alcoholic liver disease. Hepatology 1994;20(1 Pt 1):105–10.
Pageaux, GP, Michel, J, Coste, V, et al. Alcoholic cirrhosis is a good indication for liver transplantation, even for cases of recidivism. Gut 1999;45:421–6.
Goldar-Najafi, A, Gordon, FD, Lewis, WD, et al. Liver transplantation for alcoholic liver disease with or without hepatitis C. Int J Surg Pathol 2002;10:115–22.
Jain, A, DiMartini, A, Kashyap, R, et al. Long-term follow-up after liver transplantation for alcoholic liver disease under tacroimus. Transplantation 2000;70:1335–42.
Pereira, SP, Williams, R. Alcohol relapse and functional outcome after liver transplantation for alcoholic liver disease. Liver Transpl 2001;7:204–5.
Dhar, S.Omran, L, Bacon, BR, et al. Liver transplantation in patients with chronic hepatitis C and alcoholism. Dig Dis Sci 1999;44:2003–7.
Tang, H, Boulton, R, Gunson, B, et al. Patterns of alcohol consumption after liver transplantation. Gut 1998;43:140–5.
Fabrega, E, Crespo, J, Casafont, F, et al. Alcoholic recidivism after liver transplantation for alcoholic cirrhosis. J Clin Gastroenterol 1998;26:204–6.
Kumar, S, Stauber, RE, Gavaler, JS, et al. Orthotopic liver transplantation for alcoholic liver disease. Hepatology 1990;11:159–64.
Bird, GL, O'Grady, JG, Harvey, FA, et al. Liver transplantation in patients with alcoholic cirrhosis: selection criteria and rates of survival and relapse. BMJ 1990;301:15–17.
Knechtle, SJ, Fleming, MF, Barry, KL, et al. Liver transplantation for alcoholic liver disease. Surgery 1992;112:694–701.
Platz, KP, Mueller, AR, Spree, E, et al. Liver transplantation for alcoholic cirrhosis. Transpl Int 2000:13(Suppl 1):S127–30.
Gerhardt, TC, Goldstein, RM, Urschel, HC, et al. Alcohol use following liver transplantation for alcoholic cirrhosis. Transplantation 1996;62:1060–3.
Berlakovich, GA, Steininger, R, Herbst, F, et al. Efficacy of liver transplantation for alcoholic cirrhosis with respect to recidivism and compliance. Transplantation 1994;58:560–5.